癌症研究
结直肠癌
奥沙利铂
线粒体
PLK1
粒体自噬
细胞
细胞内
生物
细胞凋亡
医学
ESCRT公司
萌芽
细胞生长
化学
癌细胞
癌症
细胞生物学
抗药性
细胞器
自噬
干细胞
前列腺癌
平衡
作者
Yueying Yang,Jing Liang,Lu Wang,H Zhang,Zhiruo Zhang,Yang Liu,Rui Zhu,Wen Xu,Shaohua Xu,Dejuan Sun,Ke Xiang,Yali Wang,Zhimin Fan,Zheng Wang,Hua Li,Lixia Chen
摘要
ABSTRACT Oxaliplatin (L‐OHP) is a first‐line chemotherapeutic agent for advanced colorectal cancer (CRC) and postoperative adjuvant therapy. However, acquired L‐OHP resistance remains a clinical obstacle. Here, we identify Tubocapsenolide A (TA), a natural withanolide isolated from Tubocapsicum anomalum , as a promising antitumor agent that suppresses CRC growth and sensitizes L‐OHP‐resistant CRC to L‐OHP. Using a PROTAC‐based target deconvolution strategy, we identify PLK1 as a direct molecular target of TA. PLK1 is elevated in L‐OHP‐resistant CRC and is associated with reduced patient sensitivity to L‐OHP. Mechanistically, elevated PLK1 promotes CEP55 Ser436 phosphorylation and facilitates ESCRT recruitment to nuclear and mitochondrial budding sites. This process facilitates the clearance of L‐OHP‐induced damaged components through nuclear budding and TOM20 − /PDH + mitochondrial‐derived vesicles, thereby contributing to organelle homeostasis and cell survival. By inhibiting PLK1, TA interferes with this vesicle‐associated damage clearance process, leading to intracellular accumulation of damaged components. This damage accumulation is accompanied by nucleolar stress and mitochondrial dysfunction, ultimately contributing to cell death. Collectively, our findings identify a previously unappreciated role of the PLK1–CEP55–ESCRT axis in vesicle‐associated damage clearance during L‐OHP resistance and support this axis as a potential therapeutic target. TA represents a promising lead compound for overcoming L‐OHP resistance in CRC.
科研通智能强力驱动
Strongly Powered by AbleSci AI